Jump to content

PSYLO-4001

Add links
From Wikipedia, the free encyclopedia
PSYLO-4001
Clinical data
Other namesPsylo-4001; PSYLO4001; XYL-4001; XYL4001;
Routes of
administration		Unspecified[1]
Drug classSerotonin receptor agonist; Non-hallucinogenic serotonin 5-HT2A receptor agonist; Psychoplastogen

PSYLO-4001 is a non-hallucinogenic serotonin 5-HT2A receptor agonist and psychoplastogen which is under development for the treatment of depressive disorders such as major depressive disorder.[1][2][3] Its route of administration is unspecified.[1] The drug is being developed by Xylo Bio (formerly known as Psylo).[1][2][3] As of January 2025, it is in the preclinical research stage of development.[1][2] Its chemical structure does not yet appear to have been disclosed.[1]

See also

[edit]

References

[edit]
  1. ^ a b c d e f "Psylo 4001". AdisInsight. 21 January 2025. Retrieved 16 February 2025.
  2. ^ a b c "Delving into the Latest Updates on PSYLO-400X with Synapse". Synapse. 25 January 2025. Retrieved 16 February 2025.
  3. ^ a b "Next generation neuroscience for transformative treatments". PSYLO. 28 October 2024. Retrieved 16 February 2025.
[edit]



Stub icon

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

Retrieved from "http://en.wiki.x.io/w/index.php?title=PSYLO-4001&oldid=1275992863"